MedTrace Logo

Multimodal Magnetic Resonance Imaging Study on the Neural Mechanisms of Remission in Children With ADHD

NCT05229627 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2022-02-08

No results posted yet for this study

Summary

Attention-deficit/hyperactivity disorder(ADHD) is highly prevalent among children and adolescents and often associated with poor long-term outcomes in adulthood. it is thus a serious public health problem. Methylphenidate(MPH) and Atomoxetine(ATX) are most frequently used for treating ADHD in many countries but the individual treatment response varies. Some patients present good response to either MPH or ATX with minimal or no symptoms left and optimal functioning(remission) after treatment, while others are poor responders to one of the two or even both. The underlying mechanism for the heterogenous responsiveness remains unknown. Thus we proposed to use multimodule magnetic resonance imaging(MRI) technology to explore the neural mechanisms of remission in children with ADHD treated with MPH or ATX.

Conditions

  • ADHD

Interventions

DRUG

MPH

the drug would be prescribed to patients without any contraindication

DRUG

ATX

the drug would be prescribed to patients without any contraindication

Sponsors & Collaborators

  • Hangzhou Normal University

    collaborator OTHER

  • Peking University Sixth Hospital

    lead OTHER

Principal Investigators

  • Qingjiu Cao, PhD · Peking University Sixth Hospital

Eligibility

Min Age
6 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2022-12-31
Completion
2023-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05229627 on ClinicalTrials.gov